menu
menu
Create an account
Log In
Donate
You're on VON's public site. To go to our logged in area, click
here
Who We Are
arrow_drop_down
About Us
Our Impact
Member Map and Member List
Case Studies
Newsletter
Directors and Advisors
Staff List
Contact Us
What We Do
arrow_drop_down
Overview
Databases and Reporting
Overview
Database Summaries
Quality Improvement and Education
Overview & All Programs
All Care is Brain Care
QI Foundations
Responding to NAS
Grand Rounds
All Care is Brain Care
Collaborative Overview
Reducing Pain and Pokes
Neuroprotective Lung Strategies
Promoting Parental Wellbeing and Health Equity
Bundling Care to Reduce IVH
Optimizing Neurodevelopment for Infants with BPD
Institute for Evidence-Based Practice
Libraries
All VON Libraries
Health Equity
Publications
NICU by the Numbers
Cochrane at VON
Improvement Library
Tools
Manuals and Forms
eNICQ 6
Week 36 Calculator
Fahrenheit to Centigrade Conversion Table
Transfer Codes
Neonatal Drug Concentrations
Group Services
Global Health
Join Us
arrow_drop_down
Membership Benefits & Tiers
Quality Circle
Global Health
Membership FAQs
Follow Us On Social Media
search
Doxapram versus methylxanthine for apnea in preterm infants
Post navigation
Doxapram treatment for apnea in preterm infants
Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates
